Corrigendum to "The risks and benefits of hormone replacement therapy before and after a breast cancer diagnosis".
- Published in:
- 2021
- Publication type:
- Correction Notice
Works matching IS 20533691 AND DT 2021 AND VI 27 AND IP 1
Results: 9
1
2
News and views.
- Published in:
- 2021
- By:
- Publication type:
- journal article
3
Vision for menopause care in the UK.
- Published in:
- Post Reproductive Health, 2021, v. 27, n. 1, p. 10, doi. 10.1177/2053369121989230
- By:
- Publication type:
- Article
4
Impact of the COVID-19 pandemic on the delivery of menopause education and training.
- Published in:
- 2021
- By:
- Publication type:
- Editorial
5
BMS, IMS, EMAS, RCOG and AMS joint statement on menopausal hormone therapy and breast cancer risk in response to EMA Pharmacovigilance Risk Assessment Committee recommendations in May 2020.
- Published in:
- 2021
- By:
- Publication type:
- Letter
6
Targeting insulin resistance with selected antidiabetic agents prevents menopausal associated central obesity, dysglycemia, and cardiometabolic risk.
- Published in:
- Post Reproductive Health, 2021, v. 27, n. 1, p. 45, doi. 10.1177/2053369120982753
- By:
- Publication type:
- Article
7
HRT and breast cancer risk – Fast facts.
- Published in:
- Post Reproductive Health, 2021, v. 27, n. 1, p. 42, doi. 10.1177/2053369120973424
- By:
- Publication type:
- Article
8
Evaluation of a tertiary and district general hospital menopause service.
- Published in:
- Post Reproductive Health, 2021, v. 27, n. 1, p. 19, doi. 10.1177/2053369120947620
- By:
- Publication type:
- Article
9
The efficacy and safety of intravaginal oxytocin on vaginal atrophy: A systematic review.
- Published in:
- Post Reproductive Health, 2021, v. 27, n. 1, p. 30, doi. 10.1177/2053369120946645
- By:
- Publication type:
- Article